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Although epilepsy has been a well-documented neurological disorder for thousands of 
years, a third of individuals with epilepsy today still have seizures that are not well managed. 
After the addition of benzodiazepines to other anticonvulsants in the 1950s, doctors have largely 
focused on treating epilepsy with medications.  But, an older treatment has been recently 
reintroduced into the medical community to help remediate seizure activity.  Interestingly, a high 
fat and low carbohydrate diet regimen called the ketogenic diet has proven to be helpful to some 
people with refractory epilepsy, that is, epilepsy that does not respond well to medications.  In a 
number of cases, individuals with epilepsy who have failed over three attempts to control their 
seizures with medication become completely seizure-free after maintaining ketosis.  
While the exact mechanism of the ketogenic diet treatment is unknown, many have their 
speculations.  The diet is directly related to the diversity and quantity of gut microbiota, and is 
indirectly related to other biochemical structures and processes like mitochondrial efficacy and 
neurotransmission.  The mechanism of action for the ketogenic diet in the treatment of epilepsy 
is likely a combination of interconnected biochemical mechanisms. 
Although the ketogenic diet poses significant side effects for a small fraction of patients, 
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1. Ancient Perspectives on Epilepsy 
 
Since its first known documentation around 2000 B.C. in Assyrian texts, epilepsy has 
been a prominent disease described in a variety of languages and cultures.  In ancient Babylonian 
texts, observers documented detailed accounts of what appeared to be seizures, and their 
apparent association with evil spirits.  The Mesopotamians used the word ​antasubbu​, relating to 
“the hand of sin and the God of the Moon,” to describe a seizure (Jonathan Bird, 1991).  Because 
seizures were believed to be caused by supernatural forces, individuals with epilepsy were 
treated spiritually or disregarded entirely in an effort to keep the evil spirits from affecting others 
(Edward H. Reynolds, 2005).  Until the Hippocratic Collection of manuscripts was published in 
400 B.C., epilepsy was exclusively documented as a magical phenomenon.  In one of the 
manuscripts entitled ​The Sacred Disease​, the author was the first to suggest a physical cause of 
epilepsy rather than a supernatural one.  “It is not, in my opinion, any more divine or more 
sacred than any other diseases, but has a natural cause… Its origin, like that of other diseases, 
lies in heredity… the fact is that the cause of this affection… is the brain” (“On the Sacred 
Disease,” translated by Francis Adams).  The author argued that epilepsy was not actually a 
“sacred disease” and did not have a true connection to supernatural powers.  To rid the body of 
seizures, he suggested, people should administer “whatever is most opposed… and not that 
which favors and is allied to it.”  At that time, healers and doctors used environmental elements 
such as wind direction, heat and cooling, and food as disease remedies.  Because seizures are 





other diseases, suggested the author (Francis Adams, n.d.).  Regardless of the opinions in the 
Hippocratic Collection, society continued to believe in the supernatural cause of epilepsy for 
centuries.  Even in the New Testament that was written a few centuries later, epilepsy was still a 
feared disease; “when [someone] sees a madman or an epileptic, he gives a shudder, and spits 





















2. The 19th Century: The Classification of Epilepsy as a Neurological Disease 
 
The first significant modern accounts that established a biological cause of epilepsy came 
in the 19th century.  Robert Bentley Todd distinguished three different types of convulsions and 
described a phenomenon involving hemiparesis following a seizure, known today as Todd’s 
paralysis.  Further, he asserted a connection between epilepsy and the brain in his 1849 scientific 
publication entitled ​On The Pathology and Treatment of Convulsive Diseases​.  “We can localize 
the primary disturbance in the epileptic paroxysms… namely the hemispheric lobes and the 
mesocephale” (Robert Bentley Todd, 1849).  John Hughlings Jackson, an English neurologist, 
described the migration and sequence of motor features in a focal seizure in 1868.  Jackson 
suggested that these seizures did not come from just one cortical region, but instead traveled 
throughout the cortex, in areas that corresponded to the body parts affected during the seizure 
(​An Introduction to the Work of John Hughlings Jackson​, 2007).  Through studying epilepsy in 
animals, neurologist Charles-​Édouard ​Brown-S​équard proposed a hereditary component of 
epileptic convulsions.  ​In the middle of the 19th century, French psychiatrist Jean Esquirol and 
his contemporaries, Calmeil and Georget, differentiated between somatosensory events, episodes 
of confusion or behavioral arrest, and motor events.  Esquirol was among the first to suggest 
hospitalization in treating and managing epilepsy rather than imprisonment.  Concurrent research 
on the electrophysiology of epilepsy by German physicians Eduard Hitzig and Gustav Fritsch 
also cast doubt on the supernatural hypothesis of epilepsy that dominated social thinking at that 





field, society was slow to accept this theory.  Throughout the late 1800s, people with epilepsy 
were still labeled as “criminally insane” and thus were commonly incarcerated (Owsei Temkin, 
1945).  Treatments rooted in neurology were still exceptions even at the turn of the century. 
Physicians and healers still used herbal substances and environmental elements to treat epilepsy, 





















3. The 20th Century: The Rise of Surgery and Pharmacological Treatments for Epilepsy 
 
Great advances in epilepsy treatment arose in the early 20th century.  Before the 1900s, 
surgical procedures were used sparingly in attempt to treat extreme cases of epilepsy.  The risk 
of infection, the logistical complexity of epilepsy surgery, and the challenge of locating specific 
brain tissue to remove discouraged physicians from treating epilepsy with surgery.  Trephination 
was also documented as a successful treatment method, although it was likewise unpopular, 
probably due to the incredible skill needed to complete the operation (William Feindel et al., 
2009).  Simultaneous advances across Europe in the beginning of the 20th century helped 
formalize one of the first neural procedures aimed specifically to remediate seizure activity: the 
partial lobectomy.  A German neurosurgeon, Fedor Krause, proposed that removing the cortical 
area that causes seizure activity called the ictal zone would successfully terminate seizure 
activity.  Building upon this hypothesis, Krause’s contemporaries focused on localizing 
problematic brain tissue.  Physicians and scientists across the world were racing to invent a 
technology that would allow physicians to observe brain activity non-invasively.  The first 
electrophysiological monitoring device to do this successfully was the electroencephalogram 
(EEG) invented in 1924 by German psychiatrist Hans Berger.  By using the EEG, he quickly 
became a pioneer in recording the electrophysiology of human brains.  While Berger’s 1929 
publication detailing his EEG method and results was thorough, it was not widely accepted until 
almost a decade later when others, including Adrian and Matthews, Fischer and Lowenbach, and 





classification of a seizure in concert with the epileptiform activity (Benjamin G. Zifkin, 2009). 
Around the same time in 1928, Wilder Penfield and William Cone created the Montreal 
Procedure, a revolutionary surgical approach for epilepsy.  In this approach, physicians used 
local anesthesia to expose potentially epileptogenic cortical area while the patient remained 
awake and alert in the surgical theater.  Then, a small section of tissue was stimulated with 
electric currents that either produced a seizure or a motor convulsion.  If the induced seizure had 
the same clinical features as a typical epileptic seizure for that patient, the stimulated tissue was 
removed.  The Montreal Procedure greatly improved the precision of epilepsy surgery and was 
one of the first accounts of connecting seizure semiology with specific cortical areas (Lady 
Diana Ladino et al., 2018).  
At the same time, advances in anti-epileptogenic medications enabled people with 
epilepsy to gain seizure freedom for the first time.  Although potassium bromide was first used in 
the 19th century to treat epilepsy, it wasn’t until the early 1900s that the use of medications was 
normalized.  In 1912, phenobarbital was the first widely-synthesized pharmacological treatment 
for epilepsy.  A modified form of barbituric acid, phenobarbital aimed to decrease neural 
excitation through sedation (Zifkin, 2009).  This medication was the primary epilepsy treatment 
for nearly two decades, until Tracy Putnam of the Boston City Hospital discovered phenytoin, an 
anti-epileptic drug (AED) that was less sedative.  Scientists in the 1950s began a significant push 
to discover and release more AEDs, and as a result, carbamazepine, ethosuximide, and sodium 





were the most popular treatments for epilepsy.  Scientists introduced a second round of AEDs in 
























4. History of Dietary Treatments for Epilepsy 
 
While surgical and pharmacological treatments for epilepsy were most distinguished 
throughout the latter half of the twentieth century, a third type of treatment option that arose in 
ancient medicine was reintroduced during the former half.  For centuries, it was believed that the 
epilepsy could be cured only through dietary changes and herbal remedies.  In 1911, French 
physicians Guelpa and Marie sought to study a common belief of the cause of epilepsy: fasting. 
Though their research documentation was brief, they discovered that seizures were less severe 
upon starving the participants (James Wheless, 2008).  In the following decade, a few others 
reproduced Guelpa and Marie’s results, and noted that seizure activity for most participants 
decreased around three days after the starving began.  An American physician, Hugh Conklin, 
believed that epilepsy was caused by toxins in the body that damaged cortical areas in the brain. 
As a result, he attempted to cure epilepsy by starving his patients “as long as their physical 
condition allow[ed] it” (Emmanoiul Magiorkinis et al., 2014).  For individuals with severe 
epilepsy that was untreatable with potassium bromide or phenobarbital, starving was a feasible 
treatment option in the first two decades of the twentieth century.  However, physicians quickly 
noticed that fasting was not sustainable.  Thus, they began to focus next on identifying the 
antiepileptogenic agents present during starvation such as neuroprotective biomarkers (ibid).  In 
1921, endocrinologist Rollin Woodyatt was studying diet in people with diabetes when he 
discovered that the levels of two ketones, acetone and beta-hydroxybutyric acid, were greatly 





being starved (George Henderson, 2016).  During that same year, Dr. Russell Wilder of the 
Mayo Clinic reported that the anticonvulsant effects of starvation could be reproduced using a 
diet that created ketones in the body.  Named by Wilder for its ability to cause ketosis, the 
ketogenic diet became a possible treatment option for some people with epilepsy.  It was 
Wilder’s colleague, M.G. Peterman, who was the first to evaluate the effects of the ketogenic 
diet on epilepsy in a clinical experiment in 1924.  In Peterman’s study, seven of the twenty 
participants on the ketogenic diet became seizure free.  Peterman also noted a number of 
unsuspected benefits of the diet, including “mental development… [that was] exceptionally 
good… decrease in irritability, and an increased interest and alertness” (Wheless, 2008).  For the 
next decade, the ketogenic diet was used as a somewhat common epilepsy treatment in addition 
to the two medications phenobarbital and phenytoin.  After the first push for an improvement in 
drug therapy in the 1950s, the ketogenic diet quickly became obsolete in treating people with 
epilepsy.  With at least ten new anti-epileptic medications on the market, epilepsy for most was 
manageable only by taking a daily pill.  Now, there were treatments that generated fewer side 
effects and were far less demanding than the ketogenic diet.  
Despite the significant decline in dietary treatment research during this time, there were a 
few significant advances.  In noticing that the restrictiveness of the ketogenic diet was the 
principal reason for the lack of patient interest in the diet, one physician wanted to explore other 
dietary regimens that still produced ketones but were more clinically practical.  Dr. Peter 
Huttenlocher of the University of Chicago created a diet variant called the medium-chain 





unfortunately did not result in a subsequent reestablishment of the ketogenic diet or its variants 
as treatments for epilepsy.  Then, in 1994 after NBC’s ​Dateline​ aired an episode about the 
ketogenic diet, dietary treatment was reintroduced into society.  Since the airing of the ​Dateline 
episode, the ketogenic diet has not only been used medically as a treatment for epilepsy, but also 
socially as a weight loss regimen (James W. Wheless, 2008).  
In recent years, the ketogenic diet has been used most frequently to help manage the third 

























5. Clinical Definitions of Epilepsy 
 
According to the International League Against Epilepsy (ILAE) and the International 
Bureau for Epilepsy (IBE), a seizure is a “transient occurrence of signs and/or symptoms due to 
abnormal excessive or synchronous neuronal activity in the brain” (Fisher et al., 2005).  While 
seizures are most often imagined as the full-body clinical manifestation of abrupt body-jerking 
with perhaps foaming at the mouth, hand clenching, and eye deviation, they can take on many 
physical forms.  Regardless of seizure type, all seizures have a clear beginning, middle, and end, 
and these distinct periods can often be determined clinically and by an electroencephalogram 
(EEG).  Epilepsy is classified by the occurrence of at least one seizure and an elevated risk of 
seizure recurrence.  This  “enduring alteration in the brain” that suggests an increased probability 
of more seizures is critical in diagnosing epilepsy for individuals who have only experienced one 
seizure (ibid).  According to the Epilepsy Foundation, a person can also be considered to have 
epilepsy if they have two seizures that occur more than twenty-four hours apart (“A Revised 
Definition of Epilepsy,” 2014).  
Seizures are classified under one of three different general categories based on their first 







Figure 1:​ Expanded classification of seizure types from ILAE.  Adapted from ‘Operational 
classification of seizure types by the International League Against Epilepsy: Position Paper of the 




Focal seizures can involve a stereotyped behavior, like one-sided arm jerking, and are 
manifested on the EEG as clearly initiated from one cortical region. They can be further 
classified into seizures with awareness, which pertains to individuals who retain any level of 
awareness during a seizure, or impaired awareness, which describes those who do not retain any 
awareness during a seizure.  
Generalized seizures engage bilateral networks immediately, and, like focal seizures, can 
be classified as motor or nonmotor.  Usually, clinical manifestations of a seizure can point 
clinicians towards classifying that seizure, and the EEG results can confirm this categorization 
(Fisher et al., 2017).  Classifying a seizure can help diagnose an individual with a specific 







Tonic-clonic seizures and epileptic spasms are classified in all three seizure categories, 
rendering them challenging to diagnose solely via clinical presentation.  While the earliest 
clinical sign of a seizure may help classify that seizure, it may not be the most prominent part of 
the epileptic event.  For example, a quick behavioral arrest can become a generalized 
tonic-clonic seizure with stereotyped, rhythmic limb jerking.  Accordingly, this particular seizure 
may be classified as “focal onset with secondary generalization.”  
Epilepsy syndromes describe a group of features that include seizure type, etiology, 
family history, and EEG characteristics.  Determining seizure etiology can be useful in both 
seizure classification and specific epilepsy syndrome diagnosis.  Seizures of structural etiology 
are caused by abnormal neural structures that are distinguishable through brain imaging.  These 
structural abnormalities can be caused by either genetic lesions or malformations, or acquired 
through traumatic events such as brain injury or stroke.  Some patients with structural brain 
abnormalities may be candidates for epilepsy surgery, depending on the size, shape, and location 
of the lesion(s).  As genetic testing is becoming more accessible and advanced, many epilepsies 
have recently been classified with genetic etiology.  The mutation of specific genes, like 
PCDH19, SCN1A, and KCNQ2, cause seizures with predictable clinical features and age of 
onset, which allows clinicians to sometimes classify genetic epilepsies even before genetic 
testing.  There are, however, a number of genetic mutations that likely cause epilepsy that have 
not yet been identified.  Genetic epilepsy can also be inherited through complex inheritance 
patterns.  According to ILAE, epilepsy of infectious etiology is the most common cause of 





setting of an infection such as HIV or cerebral malaria.  Lastly, metabolic and immune seizure 
etiologies describe seizures that are symptoms or complications of other disorders.  Clinical 
presentation, EEG characteristics, family history, and genetic testing allow clinicians to identify 
the etiology of a given seizure (Ingrid E. Scheffer et al., 2017).  
The diagnosis of an epilepsy syndrome can be helpful for many reasons, such as seizure 
management, family planning, and patient prognosis.  Epilepsy can begin at any time, including 
the neonatal period, and can have an expected prognosis of seizures for just weeks to life 
(“Epilepsies: diagnosis and management,” 2012).  For example, benign familial neonatal 
epilepsy is characterized by seizures around day 3 of life and are caused by mutations to two 
genes that are related to potassium channels (S.F. Berkovic, 2004).  Individuals with this type of 
epilepsy only experience seizures for their first one to four months of life, and thus, do not 
require an epilepsy management plan for childhood and beyond.  A different epilepsy syndrome, 
Dravet Syndrome, is usually caused by an SCN1A gene mutation and has an entirely different 
prognosis than benign familial neonatal epilepsy.  While it also begins in infancy, Dravet 
Syndrome has a more intense symptome profile that will likely persist throughout the life of the 
individual.  Other symptoms and comorbidities of Dravet Syndrome include behavioral and 
developmental delays, lack of muscle tone that leads to balance and mobility issues, delayed 
speech, and sensory integration disorders.  Due to this symptom profile, physicians often begin 
aggressive treatment plans as early as possible as to minimize cognitive effects and other delays 
related to Dravet Syndrome.  These plans include the use of AEDs, especially clobazam, valproic 





etiology for an individual with epilepsy can help define his or her seizure disorder, and 






























6. Initiation and Clinical Logistics of the Ketogenic Diet 
 
The ketogenic diet is a high-fat, low-carbohydrate dietary plan used today both socially 
and to treat refractory epilepsy in pediatric patients.  Historically, patients initiated the diet 
through a hospital admission and a subsequent 24 to 48 hour fast.  Then, the diet was 
administered incrementally in the hospital through an increase in fat intake until the full 4:1 ratio 
was achieved (E. Lee et al., 2016).  While this approach is most traditional, it may not be the 
most effective.  There is some evidence that a gradual diet initiation is at least equally effective if 
not more effective than a fasting initiation (Suvasini Sharma and Puneet Jain, 2014).  In the 
course of treatment, “fasting is no longer considered necessary to begin the diet” (Zupec-Kania 
2008).  Gradual initiation is the contemporary option for ketogenic diet initiation that increases 
dietary fat content throughout a few days before attaining the 4:1 diet ratio without initial fasting. 
Unlike the patients following a fasting initiation, those using a gradual initiation plan are able to 
eat one hundred percent of calories in each meal during this period.  The gradual protocol yields 
fewer and less intense side effects like vomiting and hypoglycemia, and is more tolerable when 
compared with the fasting initiation protocol (A.C.G.Bergqvist, 2005).  Some studies have 
reported a gradual calorie increase during the initiation phase with the 4:1 ratio beginning on 
Day 1.  Regardless of diet initiation plan, the patient may remain in the hospital for one to two 
weeks for teaching and observation, but are typically discharged after three to five days (Eunjoo 
Lee, 2016).  Ketonuria is observed in patients between 24 and 48 hours after diet initiation and 





should remain the same throughout the dietary treatment period.  During the diet initiation, the 
patient and family meet with a dietitian to solidify a dietary plan specific to the patient.  As the 
ketogenic diet is most effective when the 4:1 ratio is attained, devising and adhering to a realistic 
dietary plan is crucial.  Patient and family compliance are necessary for treatment efficacy, and 
the dietitian may be consulted as the patient is monitored during treatment.  It is also necessary to 
educate both the patient and the caregivers about nutrition and the possible side effects of the 
diet, especially considering the young average age of treatment initiation.  Throughout the course 
of the diet, nutritional assessments and blood work are required to ensure healthy growth and 
minimal side effects (Zupec-Kania, 2008).  
The most prominent dietary treatment for epilepsy is the “classical ketogenic diet” also 
known as the “4:1 diet.”  This feeding plan contains a ratio of four grams of fats to every one 
gram of protein and carbohydrates.  As it is challenging for some patients to ingest a large 
amount of fat in their diets, patients who do not eat by mouth (via gastrostomy tube, etc.) find the 
transition to the ketogenic diet easier (ibid).  Some older patients report that the 4:1 diet is too 
challenging and may be advised to try the 3:1 diet or another ketogenic diet variant such as the 
modified Atkins diet (MAD) or low glycemic index treatment (LGIT).  These diet variants 







Figure 2:​ Macronutrient composition for the ketogenic diet (KD), modified Atkins diet (MAD), 
and low glycemic index treatment (LGIT).  Adapted from Lee E, Kang H, Kim HD. Ketogenic 




The ketogenic diet is rarely used for more than a few years.  Patients typically see a 
decrease of seizure activity within a few weeks, however, the best results are achieved after a 
few months or longer.  Because the diet involves significant dietary and lifestyle changes, 
patients seem more reluctant to continue this treatment if there are not remarkable benefits. 
Similar to their management of pharmacological treatments, physicians aim to eliminate the diet 
once the patient remains seizure free.  Most often, individuals are on the ketogenic diet for three 
to twelve months (ibid).  
The diet efficacy is assessed clinically through parent documentation in seizure journals. 
Blood work, including ketone levels, and frequent EEGs are used to monitor biochemical and 








7. Animal Studies in Dietary Treatment of Epilepsy 
 
Animal studies allow clinicians to evaluate more dramatic fat:lipid ratio diet variants than 
the standard 4:1 diet.  Furthermore, the use of animals is advantageous to evaluate methods of 
provoking seizures in both animal and human models.  
Research conducted by scientists from Johns Hopkins School of Medicine in 2010 
focused on determining the role of intermittent fasting compared with that of the ketogenic diet 
in anti-epileptogenesis.  Mice were assigned to one of four groups: control, calorie-restriction by 
intermittent fasting, calorie-restriction by decreasing the amount of food intake per meal, and 
unlimited 6.5:1 fat:protein diet.  Researchers implemented four different seizure tests on different 
individuals across all groups: the 6Hz test, intraperitoneal kainic acid, intravenous 
pentylenetetrazol and kainic acid, and maximal electroshock threshold.  These tests induced 
seizures and helped evaluate the efficacy of each diet variant.  For the 6 Hz test, the ketogenic 
diet group had improved protection from seizure activity, whereas the two calorie restriction 
groups experienced more easily-provoked seizures than the control group.  Interestingly, the 
ketogenic diet had no effect on seizure activity in protection against the kainic acid tests, 
suggesting a distinction between the mechanisms of epileptogenesis in the 6 Hz and kainic acid 
tests.  Where the 6 Hz test appeared to activate forebrain structures, kainic acid tests triggered 
activity in the hippocampus.  Because the ketogenic diet was initially created to mimic the 





through intermittent fasting and also through food deprivation at scheduled meals either did not 
improve or actively reduced the seizure threshold (Adam L. Hartman et al., 2010).  
Kirk Nylen and colleagues from the University of Toronto conducted a similar study to 
compare the effects of the 4:1 and 6.3:1 diet in both adult and young rats.  Using the 
pentylenetetrazol (PTZ)  infusion test, they determined that the 6.3:1 diet elevated seizure 
thresholds in young rats but not in adult rats.  This distinction between groups may have been 
related to the failure of the adult rats to reach the therapeutic range of beta-hydroxybutyrate 
levels.  In addition, the neuroprotective effects of the 4:1 diet did not statistically differ from that 
of the control group for both young and adult rats.  Because the young rats reached the 
therapeutic range of beta-hydroxybutyrate levels in this condition and did not experience an 
increase in seizure threshold, their ketone levels cannot completely account for the lack of 
seizure protection.  In addition, Nylen mentions that the PTZ test “does not model human 
intractable epilepsy,” but rather it simply allows researchers to compare the seizure threshold of 
subjects in each group.  Presumably, this limits the external validity of this experiment, as 
comparing the effects of the ketogenic diet on this rat sample may or may not relate to actual 












8. Human Experiments in Dietary Treatment of Epilepsy 
 
In the last decade, numerous studies have been performed to evaluate the clinical effects 
of the ketogenic diet.  Specifically, researchers aimed to evaluate the efficacy of the traditional 
4:1 diet in humans and compare the outcomes of the 4:1 diet with that of other diet variants, such 
as the 3:1 diet and the modified Atkins diet, in pediatric populations.  
In 2008, Elizabeth G. Neal and her colleagues from the Great Ormond Street Hospital in 
the UK studied the use of the 4:1 ketogenic diet in 103 children who had greater than seven 
seizures per week and who failed at least two antiepileptic drugs.  The two experimental groups 
in this study received either the ketogenic diet immediately or received the same diet after a 
3-month delay with no change in AED treatment during the delay period.  After three months, 
the diet group had an overall 38% reduction in seizure frequency of at least 50%, whereas the 
control group that did not receive treatment demonstrated a 37% average increase in seizure 
frequency.  The most common side effects recorded were vomiting, constipation, lack of energy, 
and hunger (Elizabeth G Neal et al., 2008). 
  Researchers from Yonsei University College of Medicine conducted a similar study in 
2007 involving seventy-six patients with refractory epilepsy to compare the 4:1 diet to the 3:1 
diet.  The diet ratios describe the lipid:non-lipid content of each diet.  After sustaining the diet 
for three months, both groups reported overall favorable outcomes.  55% of the 4:1 diet group 
and 30.5% of the 3:1 diet group, respectively, achieved complete seizure freedom.  After six 





programs.  While the maintenance rates were the same, individuals in the 3:1 diet group tolerated 
the diet significantly better than the 4:1 diet group, with only 13.9% reported gastrointestinal 
intolerance of the 3:1 group compared with 35.5% of the 4:1 group.  Interestingly, blood ketone 
levels and other laboratory findings were not significantly different between groups at the 
three-month mark.  In the second phase of the study, half of the seizure-free individuals on the 
4:1 diet were switched to the 3:1 diet, and half of the individuals who failed the 3:1 diet were 
initiated on the 4:1 diet.  After three months of remaining on a new diet variant, all of the 
patients in the original 4:1 group remained seizure-free when switched to the 3:1 variant. 
Conversely, although 75% of patients who switched to the 4:1 diet after unsuccessfully 
completing 3 months on the 3:1 diet had a 50% or greater decrease in seizure frequency, none 
became seizure free.  Ultimately, the authors recommended the 4:1 diet for better efficacy and 
the 3:1 diet only for individuals with GI problems who would not easily tolerate the traditional 
diet (Joo Hee Seo et al., 2007).  
K.N. Vykunta Raju and colleagues from a tertiary care hospital in India compared the 
effects of the 4:1 diet with an even less restrictive variant, the 2.5:1 diet, in the pediatric 
population of individuals with refractory epilepsy in 2011.  For both groups, the diet was 
initiated at the hospital using a non-fasting, gradual initiation protocol.  Both groups began on a 
1:1 program and worked up to the final diet ratio by the end of the fourth day.  The median 
seizure frequency for all participants was 11 seizures per day.  At three months, the only 
significant differences in the lipid profile were an increase in low density lipoprotein for both 





was no significant difference of seizure frequency between groups, with about 60% of both 
groups having a seizure reduction of at least 50% by three months.  Constipation was reported as 
the most common side effect.  The authors also introduced the idea of cultural food differences 
in the context of choosing an appropriate diet plan for individuals who wish to initiate the 
ketogenic diet as a treatment for epilepsy.  As this study was conducted with Indian children, 
who traditionally eat consisting of two-thirds carbohydrates, the 2.5:1 diet may be the most 
realistic plan for these children and will allow for a higher adherence to treatment (K.N. Vykunta 
Raju et al., 2011).  This variant may also be helpful for patients who have autism spectrum 
disorder (ASD) and typically eat a carbohydrate-rich diet.  
A 1989 study demonstrated the clinical differences between the 4:1 diet, MCT diet, and 
modified MCT diet in fifty-nine pediatric patients.  The modified MCT diet combined long-chain 
and medium-chain fatty acids into the diet.  Although the number of participants in each 
experimental group was small (12 to 27), all diet variants were effective for patients.  Overall, 
81% of participants had a decrease in seizure frequency by 50% or greater, and the results did 
not statistically differ between diets.  Children under fifteen years old achieved the greatest 
seizure reductions.  Fourteen of sixty-two patients had improved EEGs at three months, whereas, 
interestingly, five EEGs deteriorated.  This decline did not correspond to a subsequent clinical 
deterioration (Ruby H. Schwartz et al., 1989). 
Within the specific population of individuals diagnosed with infantile spasms, Amanda 
M. Hong and colleagues from the Johns Hopkins Hospital evaluated the clinical outcomes of the 





for the young age of the patients, as these individuals needed more protein for growth and 
development.  The patients’ parents reported an average of 1749 spasms per month before 
ketogenic diet initiation.  At the three month mark, 73% of patients had a greater than 50% 
reduction in seizure frequency, with 18% completely spasm-free.  Twenty-four months after 
patients began the ketogenic diet, 80% had a greater than 50% reduction in seizure frequency, 

























9. The Effects of the Ketogenic Diet on Gut Microbiota 
 
The gut-brain axis has been increasingly evaluated in the pathology and treatment of 
neurological diseases.  As the ketogenic diet is a dietary treatment for epilepsy, the connection 
between the gastroenteric pathway and the central nervous system may be critical in 
understanding epilepsy.  In the last decade, considerable research has been aimed at determining 
the effect of the diet on not only typical biomarkers in blood tests such as ketone levels, but also 
on gut microbiota.  These microorganisms are one clear point of connection in the gut-brain axis 
that can not only alter biochemical processes in the body directly such as digestion, but also 
adjust a number of pathways indirectly (Xiqun Zhu et al., 2017).  Gut microbiota promote 
immune system and mitochondrial function, alter neurotransmission, ketone metabolism, and 
even mood and cognition (Zhu et al., 2017, Christine A. Olson et al., 2018).  Because the 
gut-brain axis is so extensive and interconnected, the alteration of any link between these two 
body systems can cause a variety of symptoms (Zhu, 2017).  
For example, a case study from 2017 described an infant with refractory epilepsy of an 
unknown cause.  When the infant stopped eating after contracting a viral infection, his also 
seizures stopped completely.  Upon evaluation and diagnostic workup of this event, physicians 
discovered that his allergic reaction to cow’s milk resulted in seizure activity.  Eventually, the 
infant became seizure-free without AEDs while consuming cow's milk and protein-free diet 
(Raffaele Falsaperla et al., 2017).  
Gut microbiota are also related to disorders like schizophrenia, multiple sclerosis (MS), 





functions and structural characteristics ranging from memory to neuroplasticity to hallucinations. 
Studying the gut microbiota in neurological diseases and discovering additional quantifiable 
connections between the CNS and the gastrointestinal tract is pertinent to maximizing treatment 
efficacy for individuals with epilepsy (Zhu, 2017).  
A 2017 experimental study from the Shenzhen Children’s Hospital evaluated and 
compared the diversity and number of gut microbiota in healthy infants and infants with 
refractory epilepsy.  Researchers concluded that the gut microbiota of health and epileptic group 
before ketogenic diet treatment significantly differed.  Overall, the stool of epileptic patients 
contained enriched pathogens and reduced beneficial bacteria when compared with that of 
healthy patients.  Interestingly, there were several changes to the gut microbiota of the epileptic 
group after ketogenic diet treatment (Figure 3).  Specifically, ​Bacteroides​ and ​Prevotella 
increased after treatment, wherea​s Cronobacter, Erysipelatoclostridium, Streptococcus, Alistipes, 
Ruminiclostridium, Barnesiella, and Enterococcus, ​all decreased after treatment (Gan Xie et al., 
2017).  A second study also noted the elevation in ​Bacteroides​ levels post treatment, and found 
that ​Firmicutes​ and ​Actinobacteria​ decreased.  After the ketogenic diet, the gut microbiota 









Figure 3:​ Gut microbiota in P1, P2, and Health groups.  P1 is the group with epilepsy before 
ketogenic diet treatment and P2 is the same group after ketogenic diet treatment.  Adapted from 
Xie G, Zhou Q, Qiu CZ, Dai WK, Wang HP, Li YH, et al. Ketogenic diet poses a significant effect 
on imbalanced gut microbiota in infants with refractory epilepsy. World J Gastroenterol. 2017 
September 07;23(33):6164-71.  
 
Researchers from the Department of Integrative Biology and Physiology at UCLA 
conducted an experiment to examine the neuroprotection of the ketogenic diet in mice and the 
gut microbiota changes that resulted from the diet.  Feeding the mice a 6:1 diet, they used the 6 
Hz test to measure seizure thresholds of the mice.  A number of microbiota appeared in 
significantly different quantities between the control and ketogenic diet groups, as did the seizure 
thresholds after four days.  When the microbiota produced in individuals on the ketogenic diet 
were transplanted into individuals on the control diet, the mice developed significantly better 
seizure control than the control diet group.  Also, the mice that were transplanted with the control 





seizure protection than that of the control group.  Because the 6Hz test does not have high 
construct validity for human epilepsy, Spinelli and Blackford also modulated gut microbiota in 
Kcna1​-/-​ mice.  By mutating one of the subunits in a gene for the voltage-gated potassium 
channel, this mouse model more accurately mimics temporal lobe epilepsy in humans.  The 
groups of  Kcna1​-/-​ mice were treated with either a control solution or ​A. muciniphila​ and 
Parabacteroides​, two bacteria that are significantly increased during the ketogenic diet 
treatment.  Then, the mice were fed either a control diet or ketogenic diet.  Administering the 
bacterial treatment before the diet significantly decreased both the number and duration of 
seizures per day of the mice on both diets, even when compared with mice treated with 
antibiotics on the ketogenic diet (Figure 4).  
  
 
Figure 4:​ The average number of seizures per day and average seizure duration per day of Kcna1​-/- 
mice conventionally colonized specific pathogen free (SPF), treated with antibiotics (Abx), or 
treated with ​A. muciniphila​ and ​Parabacteroides​.  The mice were fed either a control diet (CD) or 
the ketogenic diet (KD).  Adapted from Olson CA, Vuong HE, Yano JM, Liang QY, Nusbaum DJ, 
Hsiao EY. The Gut Microbiota Mediates the Anti-Seizure Effects of the Ketogenic Diet. Cell. 







This suggests that gut microbiota are both “necessary and sufficient” in decreasing seizure 
frequency and duration for temporal lobe epilepsy in mice (Christine A. Olson et al., 2018).  
The gut microbiota that are altered through dietary changes such as the ketogenic diet 
directly affect seizure activity in both humans and animal models.  While quantifying and 
evaluating the gut microbiota is increasingly pertinent to understanding epilepsy, there may be 
additional points along the gut-brain axis that provide a more complete picture of the pathology 
























10. Biochemical Mechanisms 
 
The biochemical mechanism of anti-epileptogenesis of the ketogenic diet is widely 
discussed, as there are endless points of connection between the gastrointestinal pathway and the 
central nervous system.  It is likely that the ketogenic diet mediates a number of pathways that 
together create an anticonvulsant effect.  
According to a recent study from the Legacy Research Institute in Portland, OR, 
beta-hydroxybutyrate “has been considered as the main effector of the therapeutic benefits of 
ketogenic diet therapy” until 2017 (Detlev Boison, 2017).  Direct anti-seizure effects of two 
ketone bodies were first observed in animal experiments in the 1930s; since, all three ketone 
bodies have demonstrated neuroprotective effects (Suvasini Sharma and Puneet Jain, 2014).  The 
shunting of ketones in the brain to oxidative metabolism increases the number of amino acids 
created through metabolism, especially GABA.  Although ketone bodies increase inhibitory 
neurotransmission and/or decrease excitatory neurotransmission in the brain, GABA and 
glutamate levels do not significantly differ between individuals with and without epilepsy 
(Boison, 2017).  While some studies have supported the increased neural inhibition hypothesis, 
others, including some animal studies, refute it (Jong M. Rho, 2017).  
A second possible mechanism of action involving inflammatory pathways and 
peroxisome proliferator activated receptors (PPARs) has also been identified in the 
antiepileptogenic effects of the ketogenic diet in epilepsy (Boison, 2017).  In epileptogenesis, the 
production of reactive oxygen species is modified.  Because PPARs function as 





to seizure activity.  PPAR​γ, a subunit of the receptor, is activated by fatty acids.  As the 
ketogenic diet greatly increases the bioavailability of fatty acids such as arachidonic and 
decanoic acid, PPARs are activated more often during treatment.  Timothy Simeone and 
colleagues from the Creighton University School of Medicine in Omaha, NE discovered that in 
mice, the diet selectively increased the activity one of the PPARγ subunits.  Furthermore, a 
PPARγ agonist created seizure protection in mice (Timothy A. Simeone et al., 2017).  
As a number of mitochondrial disorders are comorbid with epilepsy, mitochondrial 
function is also a commonly studied point in the pathology of epilepsy (Boison 2017).  Through 
using ketones in mitochondrial energy metabolism, the ketogenic diet enhances ATP levels and 
metabolic enzyme levels (Rho, 2017).  Enhanced energy reserves in the brain are associated with 
seizure protection (Sharma, 2014). 
The role of polyunsaturated fatty acids (PUFAs) may also be significant in 
anti-epileptogenesis.  PUFAs are elevated in the body during ketogenic diet treatment as a result 
of a high fat diet.  Because PUFAs are known neuroprotective agents, they may be aiding in the 
anti-seizure effects of the ketogenic diet.  At this time, the role of PUFAs in anti-epileptogenesis 
needs further assessment (Rho, 2017).  
While the mechanisms of the ketogenic diet are still elusive, there are a number of 
hypotheses with intertwined biochemical mechanisms that may be pertinent to understanding 
epilepsy.  The modulation of mitochondrial activity, neuroinflammation, reactive oxygen 
species, neurotransmitters, and ketone bodies are demonstrated biochemical agents related to 





11. Who does the ketogenic diet benefit most? 
 
The ketogenic diet is more successful for individuals with specific clinical characteristics 
such as age and epilepsy syndrome. 
A retrospective study at the Johns Hopkins Hospital and the Johns Hopkins All 
Children’s Hospital was conducted in 2019 to analyze the effects of the ketogenic diet on 
specific epilepsies and environmental differences.  Overall, 70% of individuals on the ketogenic 
diet had a greater than 50% decrease of seizure activity after three months on the 4:1 diet. 
Individuals who were more likely to achieve drug-free diet status were younger (3.8 years vs. 4.9 
years).  Specific epilepsies that responded more significantly to this treatment included Glut1 
deficiency and Doose syndrome (myoclonic-atonic seizures).  Furthermore, patients who were 
on fewer AEDs at the start of the ketogenic diet treatment were more likely to respond to 
treatment.  Individuals who had Lennox-Gastaut syndrome or a gastrostomy tube were less likely 
to achieve drug-free seizure freedom (Lochen M. Shah et al., 2019).  
A 2010 study confirmed the improved efficacy of the ketogenic diet in a patient 
population with infantile spasms.  Individuals who had tried fewer AEDs achieved better 
outcomes overall, but this result was not statistically significant (p = 0.16).  In addition, patients 
who had an older age of spasm onset (0.5 years vs. 0.4 years) responded more positively to the 
ketogenic diet.  However, this difference in age is very small and thus may not be clinically 





Genetic generalized epilepsies, such as juvenile myoclonic epilepsy (JME) have 
demonstrated especially high response rates to the ketogenic diet (Thammongkol, 2012).  In 
addition, those with Dravet Syndrome have also responded exceptionally well.  Surprisingly, 
patients with both genetic and acquired cortical malformations respond impressively.  Patients 
with myoclonic-atonic seizures, Dravet Syndrome, lissencephaly, and hypoxic-ischemic 
encephalopathy should be initiated on the ketogenic diet as an earlier treatment option if they 
experience refractory seizures (Bara​ñano, 2008)​.  
The ketogenic diet seems to be the most promising treatment for some individuals who 
pose the greatest clinical challenges in epilepsy management.  New-onset refractory status 
epilepticus (NORSE) describes a period of prolonged seizure activity with a “continuous seizure 
lasting for more than thirty minutes or two or more seizures without full recovery of 
consciousness between any of them” that is not controlled with two medications and occurs in an 
individual with no history of epilepsy (​Ajith Cherian and Sanjeev V. Thomas, 2009).  In a 2018 
study, the ketogenic diet generated the highest number of positive effects in NORSE patients 
when compared with other antiepileptogenic therapies.  Furthermore, the diet was second most 
efficacious out of all therapy options for patients with febrile infection-related epilepsy syndrome 
(FIRES), a subcategory of NORSE.  It was almost five times as effective as plasmapheresis and 








Table 1: ​Epilepsy syndromes, conditions, and characteristics that demonstrate a probable benefit 
from the ketogenic diet.* 
 
Angelman syndrome 
Complex I mitochondrial disorders 
Dravet syndrome  
Doose Syndrome 
Fewer AEDs at time of initiation 
Glut-1 deficiency syndrome 
Febrile infection-related epilepsy syndrome (FIRES) 
Formula-fed children or infants 
Juvenile myoclonic epilepsy (JME) 
New-onset refractory status epilepticus (NORSE) 
Ohtahara syndrome 
Pyruvate dehydrogenase deficiency 
Super-refractory status epilepticus 
Tuberous sclerosis Complex 
Younger individuals 
 
*Adapted from Kossoff, E. H., Zupec-Kania, B. A., Auvin, S., Ballaban-Gil, K. R., Christina Bergqvist, A. G., 
Blackford, R., … Practice Committee of the Child Neurology Society (2018). Optimal clinical management of 
children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet 
















12. Limitations and Side Effects 
 
Like any treatment for epilepsy, the ketogenic diet may create side effects that must be 
considered when administering the diet as a treatment.  Across studies, the most common 
adverse effects reported involve gastrointestinal problems.  Vomiting is documented especially 
during the diet initiation phase, while constipation sometimes occurs during the maintenance of 
the diet.  It is not uncommon for research participants to begin a medication for constipation 
relief during the dietary treatment period.  A small percentage of participants experience kidney 
stones.  Because the diet lacks protein, there are significant and justified concerns about growth 
of young children on the ketogenic diet.  However, physicians must consider that a child’s 
growth and development may be greatly impacted by seizures, especially if the seizures occur 
frequently or last for minutes or longer.  Depending on the individual case of each child, the 
benefits of age-appropriate development that occurs when seizure frequency is reduced may 
outweigh the potential for any growth retardation as a result of the ketogenic diet (Zupec-Kania, 
2008).  After the diet is discontinued, both height and weight increase appropriately (Sharma, 
2014).  Because the ketogenic diet is usually administered temporarily for up to two years, most 
children are able to reverse any decrease in growth that may occur with the diet.  
Blood work and lab results also differ slightly for individuals on the ketogenic diet when 
compared with normal blood work profiles.  Patients on the diet tend to have an increase in 
low-density lipoprotein and reduction in high-density lipoprotein (Zupec-Kania, 2008 and 
Sharma, 2014).  Water-soluble vitamins, fiber, vitamin K, linolenic acid, and most minerals can 





increase, they typically plateau after six months of dietary treatment (Sharma, 2014).  For the 
duration of the ketogenic diet, blood work should be routinely monitored.  
As a type of medical nutrition therapy, the ketogenic diet has the potential to affect 
growth and nutrition in the human body.  While there are possible side effects of the diet that 
occur in a significant number of patients, most are minor and are typically lessened throughout 
the course of the treatment, or can be easily reversed.   Labs should be checked often to ensure 
























13. Alternate Uses, Benefits, and Future Directions 
 
Still, the ketogenic diet is used increasingly in pediatric patients with refractory epilepsy.  
The diet not only decreases seizure frequency, but also improves attention, alertness, 
concentration, and global cognition in that same population.  While these outcomes in one study 
were subjectively reported by patients and families, alertness and adaptability significantly 
increased on an objective scale.  This study also found that the longer that individuals were on 
the ketogenic diet, the more they improved in their adaptability rating, which is an “antecedent of 
future intelligence” (Dengna Zhu et al., 2016).  Unfortunately, there are no studies that evaluate 
cognitive effects of the diet after discontinuation.  
Because seizures can impact cognition, children with epilepsy are at risk for additional 
impairments due to neural disruption at a time of development.  Children with epilepsy are more 
likely to exhibit language delays, learning disabilities, behavioral problems, and even cognitive 
deterioration (K. van Rijckevorsel, 2006).  If seizures are long and/or frequent, these 
impairments can become permanent.  By decreasing or eliminating seizures in children, the 
ketogenic diet can improve overall cognitive function.  
As dietary treatments are far less common than pharmacological and surgical treatments 
in medicine, there is a “lack of awareness and acceptability” of the ketogenic diet amongst 
physicians (Sharma, 2014).   However, there has been a recent increase in research and clinical 
use of dietary treatments for not only epilepsy but also for diseases and disorders such as autism 





cancer.  Today, the use of the ketogenic diet is expanding in both research and clinical fields in 
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